Sign in
Taking people in United StatesNo phase

Molecular Profiling for Risk Stratification in Appendiceal Cancer

Key facts

Who runs it
City of Hope Medical Center
Where
Durate, United StatesSee the site
Trial code
Status
Recruiting
People taking part
400 people, planned
Started
1 May 2026
Expected to end
1 Jan 2027
Type of study
Observational, 2 groups
Treatments tested
  • DNA Methylation Profiling
  • m6A Epitranscriptomic Profiling
Record updated
29 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Patients with histologically confirmed appendiceal adenocarcinoma or appendiceal cancer
  • Availability of archived tumor tissue suitable for molecular profiling
  • Availability of tissue for DNA methylation profiling, m6A epitranscriptomic profiling, or both
  • Availability of relevant clinicopathologic data
  • Availability of survival or follow-up information when applicable
  • Age 18 years or older at diagnosis or tissue collection

Who cannot take part

  • Insufficient tissue quantity or quality for molecular profiling
  • Inadequate DNA or RNA quality for sequencing or molecular assay preparation
  • Missing essential clinicopathologic information required for analysis
  • Non-appendiceal primary tumor or metastatic tumor to the appendix from another primary site
  • Patients who do not meet institutional review board or consent requirements, if applicable

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Appendiceal cancer

This trial is currently available in United States.

  • City of Hope Medical CenterDurate, United StatesContact: Ajay Goel, MDTaking people

About the trial

What the trial wants to find out

This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort. The study includes DNA methylation profiling and m6A epitranscriptomic profiling to define molecular subtypes, evaluate associations with clinicopathologic features, and develop molecular risk scores for prognostic stratification. The primary goal is to determine whether DNA methylation- and m6A-based molecular features can complement conventional histopathologic grading and improve risk stratification.

The 2 groups in the trial

  • Appendiceal Cancer Cohort

    Patients with histologically confirmed appendiceal cancer whose archived tumor tissue specimens and clinicopathologic data are available for integrated DNA methylation and m6A epitranscriptomic profiling.

    Treatment: DNA Methylation Profiling and m6A Epitranscriptomic Profiling

  • Benign Appendix Reference Cohort

    Individuals with benign or normal appendix tissue specimens used as non-malignant reference samples for comparison of tumor-associated DNA methylation and m6A epitranscriptomic features.

    Treatment: DNA Methylation Profiling and m6A Epitranscriptomic Profiling

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Molecular Profiling for Tumor Characterization and Risk Stratification in Patients With Appendiceal Cancer
Criteria questions
Built from NCT07587268, who can take part
Record updated
29 June 2026